Early onset familial Alzheimer’s disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Early onset familial Alzheimer’s disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia https://clinicaltrials.eu/trial/study-on-the-benefits-of-amyloid-pet-imaging-with-florbetaben-18f-and-flutemetamol-18f-for-patients-with-various-types-of-dementia/ Wed, 29 Apr 2026 14:26:26 +0000 https://clinicaltrials.eu/trial/study-on-the-benefits-of-amyloid-pet-imaging-with-florbetaben-18f-and-flutemetamol-18f-for-patients-with-various-types-of-dementia/ This clinical trial is focused on studying the benefits of using a special type of brain scan called amyloid PET imaging for people with different types of dementia. Dementia is a condition that affects memory, thinking, and the ability to perform everyday activities. The study includes various forms of dementia, such as Alzheimer’s disease, vascular dementia, and dementia related to other conditions like Parkinson’s disease and HIV. The trial aims to see if amyloid PET imaging can provide better information compared to standard methods without this imaging.

Participants in the study will receive either the amyloid PET imaging or standard diagnostic procedures. The imaging involves using a solution for injection, such as Neuraceq or VIZAMYL, which contains substances like florbetaben (18F) or flutemetamol (18F). These substances help highlight certain areas of the brain during the scan. The study will observe how this imaging affects the management of daily activities and overall quality of life for those with dementia.

The trial will last for several weeks, with follow-up assessments to monitor changes in cognitive performance, quality of life, and any potential side effects. The goal is to determine if amyloid PET imaging can improve the understanding and treatment of dementia compared to current diagnostic methods. Participants will be monitored by healthcare professionals throughout the study to ensure their safety and well-being.

]]> Study on the Safety and Effects of ABBV-916 and MK-6240 for Patients with Early Alzheimer’s Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-abbv-916-and-mk-6240-for-patients-with-early-alzheimers-disease/ Wed, 29 Apr 2026 14:23:46 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-abbv-916-and-mk-6240-for-patients-with-early-alzheimers-disease/ This clinical trial is focused on studying Alzheimer’s disease, a condition that affects memory and thinking skills. The study will evaluate a treatment called ABBV-916, which is a special type of protein known as a monoclonal antibody. This protein is designed to target and reduce certain harmful substances in the brain associated with Alzheimer’s disease. The trial will also involve a comparison with a placebo, which is a substance with no active medication, to see how effective the treatment is.

The purpose of the study is to assess the safety and effectiveness of ABBV-916 in people with early stages of Alzheimer’s disease. Participants will receive the treatment through an injection into a vein, known as an intravenous injection. The study will monitor how the treatment affects the brain over time, particularly looking at changes in brain substances linked to Alzheimer’s disease. Another medication, MK-6240, will be used to help measure these changes in the brain.

Throughout the study, participants will have regular check-ups and brain scans to track their progress. The study aims to provide valuable information on whether ABBV-916 can help reduce the harmful substances in the brain and improve symptoms in people with early Alzheimer’s disease. This research is important for developing new treatments that could potentially slow down or improve the condition.

]]>